載入...
BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
The BRAF inhibitors vemurafenib, dabrafenib and encorafenib are used in the treatment of patients with BRAF-mutant melanoma. They selectively target BRAF kinase and thus interfere with the mitogen-activated protein kinase (MAPK) signalling pathway that regulates the proliferation and survival of mel...
Na minha lista:
| 發表在: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7408709/ https://ncbi.nlm.nih.gov/pubmed/32645969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071823 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|